Afrezza inhaled insulin is now available by prescription in the US, Sanofi and Mannkind Corporation have announced. The FDA approved the insulin DPI for the treatment of type 1 and type 2 diabetes in June 2014. In August 2014, Sanofi announced that it would pay Mannkind $150 million upfront and milestone payments of up to $775 million for an exclusive license for the product.
MannKind Executive Chairman Alfred Mann, who recently announced that he was stepping down as the company’s CEO, commented, “We are extremely proud to see the many years of work that went into developing Afrezza culminate in the day when it is now available to help people manage their diabetes.”
Read the Sanofi and Mannkind press release (with video).
